Most patients with corticotropin (ACTH)-dependent Cushing syndrome (CS) will have an ACTH-secreting pituitary microadenoma. Approximately 15% of patients with ACTH-dependent CS have an ectopic source of ACTH secretion. The most…
Most patients with corticotropin (ACTH)-dependent Cushing syndrome (CS) will have an ACTH-secreting pituitary microadenoma. Approximately 15% of patients with ACTH-dependent CS have an ectopic source of ACTH secretion, with the…
Approximately 15% of patients with corticotropin (ACTH)-dependent Cushing syndrome (CS) have an ectopic source of ACTH secretion, with the most common source being a bronchial carcinoid (≈25%). Ectopic CS resulting…
Most patients with corticotropin (ACTH)-dependent Cushing syndrome (CS) will have an ACTH-secreting pituitary microadenoma—50% of which are so small that they cannot be seen on magnetic resonance imaging (MRI). Pituitary-dependent…
Most patients with corticotropin (ACTH)-dependent Cushing syndrome (CS) will have an ACTH-secreting pituitary tumor. When a clear-cut pituitary tumor is found on magnetic resonance imaging (MRI) in a woman with…
Most patients with corticotropin (ACTH)-dependent Cushing syndrome (CS) will have an ACTH-secreting pituitary tumor. However, approximately 10%–15% of patients with ACTH-dependent CS have an ectopic source of ACTH secretion (see…
Corticotropin (ACTH)-dependent hypercortisolism is commonly due to an ACTH-secreting pituitary adenoma (80%–90%). Most patients with ACTH-dependent hypercortisolism are women with slowly progressive mild to moderate Cushing syndrome (CS) who will…
There is no cure for metastatic paraganglioma or pheochromocytoma (PPGL). All treatment options are associated with risks and morbidity—many times the side effects of treatment exceed tumor-related morbidity. The first…
A higher incidence of paraganglioma or pheochromocytoma (PPGL) has been reported in people living at high altitudes, indicating that environmental hypoxia could be a risk factor for development of PPGL….
There is no cure for metastatic pheochromocytoma or metastatic paraganglioma (PPGL). The first step in the management of metastatic PPGL is to assess the rate of tumor progression and, once…
